Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi (larotrectinib). The drug is indicated for the treatment
Latest articles
MarketingTroonrede 2019: meer impact als marketeer
Wie droomt er nu niet van meer impact maken? We willen iedere dag nieuwe campagnes of merkverhalen laten landen, maatschappelijke ambities groots en meeslepend uitdragen, employer branding zich zien uitbetalen in de...
GSK’s oral nicotine spray wins divided FDA panel’s backing despite abuse risks
With the federal spotlight on e-cigarette use, the FDA has grown increasingly wary of nicotine-based products with risks of abuse. That didn’t stop GlaxoSmithKline from winning a recommendation for its over-the-counter...
FDA approves Novo’s new type 2 diabetes pill
A new drug from Danish drug maker Novo Nordisk, called Rybelsus (semaglutide), has been approved by the FDA for the use in patients with type 2 diabetes to lower blood sugar levels. Rybelsus is the first drug in its...
Novartis phase III PREVENT study of Cosentyx to treat patients with axial spondyloarthritis meets 16-week primary endpoint
Novartis, a leader reimagining rheumatology and immuno?dermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with nr-axSpA
Roche wins FDA breakthrough for Gazyva in lupus nephritis
Drug originally approved as a lymphoma treatment
